NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 18,073 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 18,073 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $25.09, for a total transaction of $453,451.57. Following the transaction, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at approximately $376,350. This represents a 54.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Monday, August 25th, Louise Frederika Kooij sold 8,269 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $24.86, for a total value of $205,567.34.

NewAmsterdam Pharma Stock Up 5.2%

Shares of NASDAQ NAMS opened at $27.00 on Friday. The firm has a market capitalization of $3.04 billion, a P/E ratio of -16.67 and a beta of -0.01. The stock’s 50-day simple moving average is $22.98 and its two-hundred day simple moving average is $20.55. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.37. The firm had revenue of $19.15 million during the quarter, compared to analysts’ expectations of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. As a group, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on NAMS shares. Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Wells Fargo & Company started coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They set an “overweight” rating and a $45.00 price target on the stock. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. Finally, The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a “neutral” rating and a $27.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.55.

Institutional Trading of NewAmsterdam Pharma

A number of large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 2.4% in the second quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock valued at $408,000 after purchasing an additional 521 shares during the period. Duquesne Family Office LLC boosted its holdings in shares of NewAmsterdam Pharma by 4.0% in the second quarter. Duquesne Family Office LLC now owns 832,175 shares of the company’s stock valued at $15,071,000 after purchasing an additional 31,815 shares during the period. Exome Asset Management LLC purchased a new stake in shares of NewAmsterdam Pharma in the second quarter valued at approximately $662,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of NewAmsterdam Pharma by 3.0% in the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in NewAmsterdam Pharma by 4.5% during the second quarter. BNP Paribas Financial Markets now owns 29,277 shares of the company’s stock worth $530,000 after buying an additional 1,257 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.